Cost-utility analysis of dapagliflozin for the treatment of symptomatic chronic heart failure in Spain

Cost-utility analysis of dapagliflozin for the treatment of symptomatic chronic heart failure in Spain

Abstract Background The objective of this study was to perform a cost-utility analysis of dapagliflozin, as an add-on therapy to standard of care (SoC), compared with SoC, for patients with symptomatic chronic heart failure (HF) in Spain, including patients with reduced and preserved ejection fracti...

Full description

Saved in:
Bibliographic Details
Main Authors: Carlos Escobar, Domingo Pascual-Figal, Josep Maria Guiu-Segura, Margarita Capel, Elisenda Pomares Mallol, Christian Caudron
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Health Services Research
Subjects:
Cost-effectiveness analysis
Cost-utility analysis
Dapagliflozin
Symptomatic chronic heart failure
Spain
Online Access:https://doi.org/10.1186/s12913-025-13089-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12913-025-13089-7

Similar Items